Answers are grounded in this paper and cite their sources.
, but no additional clinically validated genetic markers of toxicity are available to date. The development of next-generation sequencing platforms opens new possibilities to highlight previously unreported genetic markers. Moreover, the investigation of the genetic variation in the patients immunological system, a pivotal target in cancer treatment, could bring notable advances in the field. This review will describe the most recent literature on the use of pharmacogenetics to increase the safety of a treatment based on FP administration in colorectal cancer patients.
No takes yet. Share an insight, caveat, or question.
Mattia et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: